Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionano Genomics, Inc. on March 23, 2021. The filing discloses the entry into a new Sales Agreement with Cowen and Company, LLC, under which the Company may offer and sell shares of its common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a corporate event rather than a financial performance report.
- Maximum Offering Amount: Up to $350.0 million in aggregate offering price.
- Commission Fee: Up to 3.0% of aggregate gross proceeds from each sale.
- Securities Involved: Common Stock, $0.0001 par value per share (Trading Symbol: BNGO).
Material Changes
The material change disclosed is the execution of an "at-the-market" (ATM) Sales Agreement. This provides the Company with a mechanism to sell shares from time to time at its sole discretion, subject to market conditions and the terms of the agreement. The Company is not obligated to sell any shares under this agreement.
Guidance, Outlook, and Risks
Management Commentary: The Company retains sole discretion over the number of shares to be issued, the dates of sales, daily limitations, and minimum price thresholds. Cowen and Company, LLC will act as sales agent or principal using commercially reasonable efforts.
Risks and Contingencies:
- Termination: The agreement may be terminated by either party upon 10 days' prior notice. Cowen may also terminate immediately in certain circumstances, including a material adverse effect on the Company's business or financial position.
- Market Conditions: Sales are subject to market conditions and the definition of an "at-the-market offering" under Rule 415(a)(4).
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of a $350 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific minimum price floors or daily volume caps.
- Monitor subsequent filings for actual sales executed under this agreement and the resulting cash proceeds.
- Check the Company's latest 10-K or 10-Q for current cash reserves and burn rate to understand the necessity of this capital raise.